Editas Medicine, Inc. (EDIT) Q2 2020 Earnings Call Transcript

Editas Medicine, Inc. (EDIT) Q2 2020 Earnings Call Transcript

The first press release announces the termination of our agreement with Allergan for the development of ocular medicines, returning full control of these programs to Editas Medicine. The second press release provides our financial results and corporate updates for the second quarter of 2020.